<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An allogeneic transplantation of CD34(+)-selected cells from peripheral blood (allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>/CD34(+)) from HLA-identical sibling donors was performed in 50 adult patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> in first complete remission (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> CR1) (n = 29), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n = 4), or <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in first <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (<z:mp ids='MP_0005481'>CML</z:mp> CP1) (n = 17) </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical results were compared to a concurrent group of 50 patients transplanted with unmodified peripheral blood progenitor cells (allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>), matched for age, diagnosis, and disease stage </plain></SENT>
<SENT sid="2" pm="."><plain>The median follow-up period was 29 months (range 1-69) </plain></SENT>
<SENT sid="3" pm="."><plain>The actuarial probability of developing <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD clinical grade II to IV was 16% (95%CI: 6-26) for the allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>/CD34(+) group and 41% (95%CI: 29-57) for the allo-<z:chebi fb="1" ids="53322">PBT</z:chebi> group (P = 0.002) </plain></SENT>
<SENT sid="4" pm="."><plain>The actuarial probability of developing extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD was 22% (95%CI: 8-36) for the allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>/CD34(+) group and 47% (95%CI: 31-63) for the allo-<z:chebi fb="1" ids="53322">PBT</z:chebi> group (P = 0.02) </plain></SENT>
<SENT sid="5" pm="."><plain>Recipients of allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>/CD34(+) had less toxicity associated with the transplant and better Karnofsky index at the last follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>For <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients, the actuarial probability of disease-free survival (DFS) for recipients of allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>/CD34(+) and allo-<z:chebi fb="1" ids="53322">PBT</z:chebi> was 65% (95%CI: 45-85) vs43% (95%CI: 28-58) (P = 0.05), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>These data provide a rationale for a randomised trial of allo-<z:chebi fb="1" ids="53322">PBT</z:chebi>/CD34(+) vs allo-<z:chebi fb="1" ids="53322">PBT</z:chebi> in <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients in early stage of the disease </plain></SENT>
</text></document>